MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ
1.800
-0.030
-1.64%
After Hours: 1.830 +0.03 +1.67% 19:51 03/28 EDT
OPEN
1.850
PREV CLOSE
1.830
HIGH
1.910
LOW
1.755
VOLUME
1.89M
TURNOVER
0
52 WEEK HIGH
1.940
52 WEEK LOW
0.5901
MARKET CAP
225.55M
P/E (TTM)
-7.6304
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATOS last week (0318-0322)?
Weekly Report · 4d ago
Atossa climbs after cancer therapy update
Atossa Therapeutics, Inc. (ATOS) climbs after cancer therapy update. A breast cancer patient who received its lead candidate (Z)-endoxifen remained cancer-free after five years of therapy. The patient started receiving the treatment in 2018.
Seeking Alpha · 03/19 19:51
Weekly Report: what happened at ATOS last week (0311-0315)?
Weekly Report · 03/18 10:42
Atossa Therapeutics Appoints Dr. Cigler, Expands Board Governance
TipRanks · 03/12 12:43
Press Release: Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. To its Board of Directors. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City. Atossa is a clinical stage biopharmaceutical company developing innovative medicines with a focus on breast cancer.
Dow Jones · 03/12 12:30
*Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors
Dow Jones · 03/12 12:30
Weekly Report: what happened at ATOS last week (0304-0308)?
Weekly Report · 03/11 10:40
Press Release: Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting in 2024. The study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with breast cancer. Data from the 40mg run-in cohort of the ongoing Phase 2 study will be presented at the AACR Annual Meeting.
Dow Jones · 03/06 13:30
More
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.

Webull offers Atossa Therapeutics Inc stock information, including NASDAQ: ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.